Positive Phase 3 PADCEV–Keytruda Bladder Cancer Data Could Be A Game Changer For Astellas Pharma (TSE:4503) [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
achieved statistically significant improvements in event-free and overall survival, with higher pathologic complete response rates and a safety profile consistent with prior data. The strength of these pivotal results could meaningfully reinforce PADCEV's role within Astellas' oncology portfolio, particularly in earlier-stage bladder cancer where treatment options remain limited. Next, we'll examine how this positive Phase 3 PADCEV–Keytruda data may reshape Astellas Pharma's investment narrative and long-term growth profile. We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. To own Astellas Pharma, you need to believe its newer oncology and specialty drugs can offset pressure from aging blockbusters and tighter pricing worldwide. The positive EV-304 PADCEV Keytruda data supports the near term oncology catalyst but does not remove bigger structural risks such as future loss of exclusivity for core brands and que
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- How Attractive Is Astellas Pharma After a 44.1% Surge and Mixed Valuation Signals? [Yahoo! Finance]Yahoo! Finance
- Reassessing Astellas Pharma (TSE:4503) Valuation After Positive PADCEV-Keytruda Phase 3 Bladder Cancer Results [Yahoo! Finance]Yahoo! Finance
- Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines [Yahoo! Finance]Yahoo! Finance
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium [Yahoo! Finance]Yahoo! Finance
- Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers SymposiumPR Newswire